Seal Rock Therapeutics discovers and develops kinase inhibitors that silence pathological cellular stress signals. Our ASK1 inhibitor, being developed for rare liver and kidney diseases, has robust preclinical efficacy and was well-tolerated in a phase 1 trial. Seal Rock’s preclinical LRRK2/ASK1 Dual Kinase (LADK) inhibitors have enhanced neuroprotective and anti-neuroinflammatory activity. They are applicable in both Parkinson's disease and ALS, whether sporadic or due to any gene mutation. In a potential safety breakthrough, simultaneously blocking both kinases eliminates kidney and lung toxicology findings seen with LRRK2 inhibition alone